HOME > BUSINESS
BUSINESS
- Santen Opens Office in Ho Chi Minh City
October 21, 2013
- Kissei, Kyorin Initiate PI Study of Overactive Bladder Treatment KEA-0447/KRP-EPA605
October 21, 2013
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
- Eisai Inc to Increase Belviq Sales Reps to 400 in US
October 17, 2013
- Toho Pharmaceutical’s Logistics Base TBC Sapporo Starts Operations: Toho Holdings
October 17, 2013
- NBI, Eli Lilly Submit NDA for SGLT-2 Inhibitor
October 17, 2013
- Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
- Otsuka Completes Acquisition of US Biotech Startup Astex
October 16, 2013
- Janssen, AZ to Copromote Prostate Cancer Treatment Abiraterone in Japan
October 16, 2013
- Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
- Santen Launches Preservative-Free Tapros Mini Ophthalmic Solution
October 15, 2013
- Kowa Files for Approval of Glaucoma Treatment K-115
October 15, 2013
- Otsuka, Lundbeck Initiate Multinational PIII Program of Novel AD Treatment Lu AE58054
October 15, 2013
- Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
- PAREXEL CEO Says Japan Will Remain as Important Market for CROs, Hopes Outsourcing Increases in Japan
October 11, 2013
- Ono to Set Up Local Subsidiary in South Korea, Eyeing Commercialization of Own Brands
October 11, 2013
- 36 Drug Makers Paid Approximately 400 Billion Yen to Doctors, Medical Institutions in FY2012; Mainly for R&D, But Also for Information
October 11, 2013
- 36 Drug Makers Spent 120 Billion Yen on Information Provision; Foreign-affiliated Companies Top Spending List
October 11, 2013
- DSP to Set Up New Anticancer Drug Sales Company in US, Eyes Launch of BBI608
October 10, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…